Quick Answer
Aurinia Pharmaceuticals Inc. reported Cash and Equivalents of $80.16 million for fiscal year 2025.
Aurinia Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $80.16M | -3.9% |
| 2024 | $83.40M | +71.1% |
| 2023 | $48.76M | -48.2% |
| 2022 | $94.09M | -59.4% |
| 2021 | $231.64M | -14.9% |
| 2020 | $272.35M | -11.0% |
| 2019 | $306.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $72.89M | +99.0% | +37.7% |
| June 30, 2025 | $52.91M | +59.1% | -20.0% |
| March 31, 2025 | $66.11M | +3.4% | +80.5% |
| September 30, 2024 | $36.63M | -19.6% | +10.1% |
| June 30, 2024 | $33.27M | -59.1% | -48.0% |
| March 31, 2024 | $63.91M | -27.6% | +40.3% |
| September 30, 2023 | $45.56M | -46.6% | -44.0% |
| June 30, 2023 | $81.39M | -46.2% | -7.9% |
- Aurinia Pharmaceuticals Inc. showed a decrease of -3.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Aurinia Pharmaceuticals Inc.’s cash and equivalents has declined by 73.8% (from $306.02 million to $80.16 million).
- The most recent figure is from Aurinia Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: